Incretin Mimetic Can Cause Severe, Disabling Joint Pain, FDA Warns
In a drug safety communication, the FDA said it has added a new warning and precaution about the risk of joint pain to the labels of all prescription drugs in the class, also known as dipeptidyl peptidase-4 (DPP-4) inhibitors.
The drugs are prescribed to patients with type 2 diabetes to help lower blood sugar.
4 Brand Groups Affected...
To view the full article, register now.